ABC · updated 1d ago

This Technology Has Not Been Cleared or Approved by the FDA and Is Not for Sale in the United

See how ABC are framing this — we run every side, so you decide. News for humans, not bots: serious, civil discussion among real people, with the context and facts you need. Don't just watch: be on the air with your own video takes, polls and predictions.

ABC

“THIS TECHNOLOGY HAS NOT BEEN CLEARED OR APPROVED BY THE FDA AND IS NOT FOR SALE IN THE UNITED”

covered 1d ago ▶ Be on the air with ABC

Watch the moment

Bloomberg News

Braham Wrights

EvidenceDad

Add your voice

Polls, predictions & fact-checks we ran live across networks — your take joins the running tally, compared across every network.

This storyWhich U.S. agency's clearance did Theranos's technology lack, per the chyron?

  1. FDA
  2. FTC
  3. SEC
  4. CDC
Guess, then reveal the answer

FDA

Theranos exploited an FDA diagnostic loophole dating to 1976.

The FDA's authority over blood-testing devices stems from the Medical Device Amendments of 1976. Lab-developed tests like Theranos's were long exempt — a gap regulators debated closing for decades before Holmes's company made it urgent.

Topic poll · all networksHow long until this FDA-unapproved technology is cleared for US sale?

  • Within a year 0%
  • One to three years 0%
  • Three to five years 0%
  • Never in the US 0%

Be the first to weigh in

A 2025 court struck down FDA's rule on lab-developed tests like Theranos's

FDA finalized the rule in May 2024, ending its decades-long leniency toward in-house lab tests. In March 2025 a Texas federal judge vacated it, and the agency chose not to appeal.

Full FDA device approval can take 3–7 years of clinical review.

The FDA's toughest pathway — Premarket Approval (PMA) — requires extensive clinical trial data proving safety and effectiveness. It costs manufacturers an average of $94 million just to complete the application.

In 2024, the FDA moved to regulate lab tests the way Theranos evaded.

For decades, lab-developed tests dodged FDA device oversight via 'enforcement discretion.' Theranos exploited this gap. The FDA's 2024 rule phases in full LDT oversight over 4 years — a direct policy legacy of the Theranos scandal.

…and 3 more when you're on the air.

The conversation

No comments yet — be the first to add your voice when you're on the air. Civil, moderated, bot-free.

LIVE ROOMS Rooms open during live coverage 1 channel ▾
ABC ▶ Be on the air